A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
- BIOLOGICAL: RSV F subunit 45 μg No adjuvant
- BIOLOGICAL: RSV F subunit 45 μg Aluminum hydroxide adjuvant
- BIOLOGICAL: RSV F subunit 45 μg MF59 adjuvant
- BIOLOGICAL: RSV F subunit 90 μg No adjuvant
- BIOLOGICAL: RSV F subunit 90 μg Aluminum hydroxide adjuvant
- BIOLOGICAL: RSV F subunit 90 μg MF59 adjuvant
- BIOLOGICAL: RSV F subunit 135 μg No adjuvant
- BIOLOGICAL: RSV F subunit 135 μg Aluminum hydroxide adjuvant
- BIOLOGICAL: RSV F subunit 135 μg MF59 adjuvant
- DRUG: Placebo
Sponsor
GlaxoSmithKline